Fumarate hydratase (FH) is a metabolic enzyme that is part of the Krebs-cycle, and reversibly catalyzes the hydration of fumarate to malate. Mutations of the FH gene have been associated with fumarate hydratase deficiency (FHD), hereditary leiomyomatosis, renal cell cancer (HLRCC), and other diseases. Currently there are no high-quality small molecule probes for studying human fumarate hydratase. To address this, we developed a quantitative high throughput screening (qHTS) FH assay and screened a total of 57,037 compounds from in-house libraries in dose-response. While no inhibitors of FH were confirmed, a series of phenyl-pyrrolopyrimidine-diones were identified as activators of human fumarate hydratase. These compounds were not substrates of fumarate hydratase, were inactive in a malate dehydrogenase counter screen, and showed no detectable reduction-oxidation activity. The binding of two compounds from the series to human fumarate hydratase was confirmed by microscale thermophoresis. The low hit rate in this screening campaign confirmed that FH is a 'tough target' to modulate, and the small molecule activators of human fumarate hydratase reported here may serve as a starting point for further optimization and development into cellular probes of human FH and potential drug candidates.
heterozygosity (LOH) in the wild-type allele by somatic mutations leads to severe reduction or absence of fumarate hydratase activity, which is followed by the increased intracellular level of fumarate. Accumulated fumarate acts as an oncometabolite to induce tumorigenesis through competitively inhibit α-ketoglutarate-dependent dioxygenase enzymes and post-translationally modify proteins by succination 6, 7 . Aside from FH deficiency and HLRCC, studies have also shown that fumarate hydratase is involved in hypertension, type 2 diabetes and diabetic kidney disease [8] [9] [10] . For example, deletion of FH in mouse pancreatic β cells leads to progressive glucose intolerance and diabetes after 6-8 weeks. In human, the fumarate level is higher in islets from donors of type 2 diabetes than the normal donors, and high glucose produce no further increase of fumarate 10 .
Currently there are no biochemically characterized inhibitors of FH, and no known activator for this enzyme. Two series of inhibitors have been reported to inhibit the activity of human 11 or Mycobacterium tuberculosis FH 12 . In an attempt to identify nutrient-dependent cytotoxic compounds, Takeuchi et al 11 screened a collection of 6,000 small molecules and discovered a new class of inhibitors of human FH (compound 1-3 with pyrrolidinone structure). In another report, Kasbekar 12 reported that two inhibitors (compound 7 and 8) were identified for the Mycobacterium tuberculosis fumarate hydratase (tbFH) after screening a collection of 479,984 small molecules.
To identify small molecule activators or inhibitors of human FH, we developed a fluorescencebased FH assay by coupling to malate dehydrogenase (MDH)/diaphorase/resazurin and optimized the assay for quantitative high-throughput screening (qHTS) in 1536-well plates. We proceeded to screen a collection of small molecule libraries to identify new activators or inhibitors of human FH. A total of 57,037 small molecular compounds were screened, and majority of hits were triaged by malate dehydrogenase (MDH) counter screen assay. One series of the activators for human fumarate hydratase was confirmed and validated in the current study. 
Materials and methods:

Reagents and chemical libraries
High-throughput screen and counter screen
For primary high-throughput screen, 3 Fluorescence from each well was normalized using enzyme-free and DMSO-treated control wells on each plate, and changes in fluorescence (∆RFU) were calculated using the difference in fluorescent signal for each well at 15 minutes versus 0 minutes.
The malate dehydrogenase counter screen was adapted from the primary high-throughput screen protocol. 3 μl MDH solution (containing 13.33IU/ml malic dehydrogenase, 0.2mM NAD, 0.067mg/ml diaphorase and 0.067mM resazurin in assay buffer (50 mM Tris pH 8.0, 5 mM MgCl2, 0.01% Brij 3)) was dispensed in each well in the 1536-well plate. Plates were incubated at room temperature for 10 minutes after compound transfer. 1 μL of substrate solution containing malic acid (160uM) was dispensed to initiate the reaction. Fluorescence was measured (ex540, em590 nm) at 0 and 5 minutes. The fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate, and ∆RFU was calculated using the difference in fluorescent signal for each well at 5 minutes versus 0 minutes.
REDOX assay
Amplex red assay was used to detect the REDOX activity of small molecules. Briefly, 2. 
Microscale thermophoresis
Recombinant human fumarate hydratase, which contains a polyhistidine tag at the C-terminus, was labeled with Monolith His-Tag Labeling Kit RED-tris-NTA kit (NanoTemper Technologies, München, Germany). Briefly, the protein was diluted to 200 nM in PBS-T buffer (137 mM NaCl, 2.5 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4;0.05 % Tween-20). The RED-tris-NTA dye was also diluted in PBS-T to 100 nM. The diluted protein and dye were mixed in 1:1 volume ratio and incubated for 30 min at room temperature (RT). After centrifuge 15,000 x g for 10 minutes at 4°C, the supernatant was transferred to a new tube and ready to use. 
In vitro ADME Studies
The physicochemical and pharmacokinetics properties of compounds were measured using the following high-throughput in vitro assays: rat microsomal stability assay, parallel artificial membrane permeability assay (PAMPA) and aqueous kinetic solubility assays. The details of these assays are described in a previous study 14 .
qHTS Data Analysis
Analysis of compound concentration-response data was performed as previously described 15 .
Briefly, raw plate reads for each titration point were first normalized relative to the no enzyme control and DMSO-only wells as follows: % Activity = ((Vcompound -VDMSO)/(VDMSO -Vno enzyme)) × 9 100, where Vcompound denotes the compound well values, Vno enzyme denotes the median value of the no enzyme control wells, and VDMSO denotes the median values of the DMSO-only wells, and then corrected by applying a NCGC in-house pattern correction algorithm using compoundfree control plates (i.e., DMSO-only plates) at the beginning and end of the compound plate stack 16 . Concentration-response titration points for each compound were fitted to a four- 
Results:
Assay design, optimization and miniaturization.
To identify activators or inhibitors of human FH, we developed a fluorescence-based FH assay, adapted from a previous study 12 . In our assay format, the FH reaction is coupled to two sequential enzymatic reactions: MDH and diaphorase reactions. In the first coupled MDH reaction, L-malate produced by FH is converted into oxaloacetate, removing L-malate from the system and driving the FH forward reaction. The reduced form of nicotinamide adenine dinucleotide (NADH) generated by MDH is utilized in the second coupled reaction by diaphorase to convert resazurin to resorufin ( Fig 1A) , with the further benefit of regenerating NAD + to drive the MDH biochemical reaction. Resorufin is strongly fluorescent, with an excitation wavelength at 530-540 nm and emission at 585-595 nm 19, 20 . Therefore, FH activity can be evaluated by measuring fluorescence signal of resorufin.
To optimize assay conditions, the initial linear velocity of the enzymatic reaction was determined in the presence of excess fumarate. We found that the enzymatic reaction was linear over 30 minutes at concentration of up to 20 nM FH enzyme (Fig 1b) . We selected 10 nM FH enzyme concentration and monitored the reaction for 15 min at room temperature (incubations not amenable to a high-throughput platform) for remaining experiments. The Km value of fumarate was determined as 41 ± 1.1 µM by monitoring reaction kinetics over a wide range of fumarate concentrations ( Fig 1C) . As we sought to identify both activators and inhibitors, the FH assay was performed with a substrate concentration near the Km value of fumarate (40µM). A known liability of coupled enzymatic assays is that small molecules appearing to be active from HTS may in fact be modulating the activity of MDH or diaphorase, rather than the target itself. To enable the triage of false positives, we developed a MDH counter-assay, omitting FH and adding the MDH substrate malate to initiate the reaction. The kinetics of the MDH counter assay were evaluated at variable concentrations of MDH enzyme and at several time points. The biochemical reaction was found to be in the linear range for the first 5-6 min at concentrations up to 20 IU/mL MDH enzyme ( Fig 1D) . The Km value of malate was determined by MDH assay as 225 ± 30 µM ( Fig 1E) . This concentration of malate was selected for the MDH counter-assay.
To assess the reproducibility and robustness of the assay, FH assay was performed in white solid bottom 1536-well Greiner microplates and statistics was analyzed. Buffer containing enzyme was dispensed into a microplate from columns 1, 2 and 5-48. The reagent without FH enzyme was dispensed into columns 3 and 4 as an enzyme-free negative control. DMSO (23 nL) was transferred into all wells, and then incubated with enzyme for 10 minutes. The reaction was then initiated by adding fumarate. The kinetics of reaction was measured at t = 0 min and t = 15 min (Table 1) . As shown in Figure 1F , signal-to-background (S/B) was 13.8, coefficient of variation was 6.1% and Z' factor was 0.83. The assay conditions result in less than 10% substrate conversion during the course of the assay. To ensure the assay is amenable to storage of reagents over the multiple hours that a qHTS assay would require to be initiated, enzymatic activity was assessed over storage times. FH was found to be unstable when stored at room temperature, rapidly losing activity within 2 h, but was quite stable when stored on ice for at least 6 hours (Supplemental Fig 1) .
qHTS screening and counter-screen
We screened six in-house libraries with a total number of 57,037 small molecule compounds in 1536-well format (Fig 2A) . The libraries include LOPAC®1280 which is the Library of Pharmacologically Active Compounds, NCATS Pharmaceutical Collection which covers 2,816 compounds from late-stage clinical trials and FDA approved drugs, NCATS Pharmacologically Active Chemical Toolbox which contains 5,099 annotated compounds with known targets or biological pathways, MIPE (Mechanism Interrogation Plate) collection with 1,912 oncology focused compounds with well-annotated primary mechanisms of action, a kinase inhibitor focused library with 977 compounds, and a small molecule screening collection with diverse scaffolds designed from novel chemical space (44,953 compounds). The assay was robust and consistent across the screening plates, with an average assay Z' factor 0.73 ± 0.09 ( Fig 2B) . The hit rate of activators was 0.1% (69 compounds), and inhibitors was 1.5% (868 compounds). The qHTS data was deposited in PubChem with AID 1347055, and you can access this assay with the following link: https://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1347055. We cherrypicked 374 compounds based on our selection criteria (active compounds and efficacy ≥ 50%, see methods) for confirmation testing. In the confirmation assay, 13 compounds were confirmed as active activators and 178 as active inhibitors. However, the majority of the confirmed hits displayed activity in the MDH counter-assay and were triaged.
Only 4 series of inhibitors and 2 series of activators survived the counter-screening process. We then plated a total of 166 analogs structurally related to the hits from our in-house library for re-testing. One series of activators was confirmed in our FH assay ( Fig 3A) and further evaluated in the follow up experiments. All other compounds dropped out during the reconfirmation assays.
Identification and validation of FH activators
The activator chemotype is composed of a series of phenyl-pyrrolo-pyrimidine-diones which are active against FH with AC50 ranging from 5.6 µM to 31.6 µM and efficacy ranging from 35% to 79% ( Table 2 ). Compounds were not active in the MDH counter assay ( Fig 3B) . No signal was detected in the absence of substrates in both assays ( Fig 4A) , which indicated neither compound was the substrate of those two enzymes (unlike tartrate, vide infra). To ensure activity was not due to impurities in the library material, four compounds (highest potency and efficacy) were procured from vendors and purified via reverse phase HPLC. The newly acquired compounds showed similar activity (Supplemental Fig 2) .
Artefactual liabilities of screening hits can be responsible for the apparent activation, such as the ability to undergo reduction-oxidation (redox) cycling. To examine whether compounds demonstrate redox activity, the amplex red assay was performed. In the assay, two compounds with weak (Walrycin B) and strong (Chloranil) redox activity were used as positive controls.
None of the hit compounds displayed detectible redox activity ( Fig 4B) .
We performed microscale thermophoresis as a biophysical assay to directly demonstrate binding of activators to FH 21 . Two compounds with high potency, NCGC00102736 (AC50 = 8.89 µM) and NCGC00117675 (AC50 = 9.98 µM) were evaluated. The dissociation constant (Kd) of NCGC00102736 was found to be 18.3 µM and NCGC00117675 was 23.3 µM ( Fig 5) .
In vitro ADME properties of FH activators.
To evaluate the physicochemical and pharmacokinetic properties of the FH activator series, we selected the four most potent compounds and tested them in a series of in vitro ADME assays.
Using automated high-throughput in vitro assays, we examined rat microsomal metabolic stability, permeability and solubility of those compounds. The half-life (t1/2) of compounds in rat hepatic microsomal stability assay ranged from 1.1 min to 7.7 min, suggesting that these compounds were metabolically unstable. The PAMPA was used as an in vitro model of passive, transcellular permeation. Two pH conditions (pH 5 and pH 7.5) were tested in this assay. All compounds scored as highly permeable (>100 x 10 6 cm/s) at pH 5 and two compounds (NCGC00102736 and NCGC00117675) showed high permeability at pH 7.4. Aqueous solubility was assessed by a high-throughput kinetic solubility assay. The value of solubility ranged from <1 µg/mL to 14.7 µg/mL, indicating these compounds had low aqueous solubility.
Evaluation of prior art compounds and artifacts
As two inhibitors of FH were reported previously, we evaluated the activity of those inhibitors in our human FH assay. We re-synthesized the compound 3 (fumarate hydratase-IN-2) which had been reported as active against human FH in a commercial in vitro assay (Ki=4.5 µM) 11 . We found compound 3 to be inactive in our biochemical assay ( Fig 6A) . Based on the core structure of compound 3, we further cherrypicked 68 analogs of this chemotype and found none of them were active in our FH assay (data not shown). In another report, Kasbekar 12 reported two inhibitors of the Mycobacterium tuberculosis fumarate hydratase (tbFH) from the same chemotype (compound 7 and 8 in their paper). We tested compound 8, which showed weak inhibitory activity at the highest concentration (IC50 = 42.2 µM and efficacy = 30.2%) in our human FH assay ( Fig 6A) . Given that enzymes from two species share identical residues in active sites and overall 59% similarity 22 , it is not surprising that compounds inhibitor targeting tbFH also showed a weak inhibitory activity against human FH.
During our HTS campaign, we identified an interesting false-positive compound, U-50488, which is a highly selective κ-opioid agonist. There are three salt forms of U-50488 in our collection. We found that the tartrate salt of U-50488 showed very high activator activity.
However, the hydrochloride and methanesulfonate salts of U-50488, also in our library, showed no activator activity ( Fig 6B) . We speculated that this activator activity might derive from the tartrate salt component, instead of compound U-50488 itself. Potassium sodium tartrate was then tested and was confirmed to produce increased activity in our FH assay ( Fig 6C) . As tartrate was reported as a substrate of FH and MDH in the 1960s 23, 24 , we hypothesized that tartrate might be utilized as the substrate of FH or MDH in our assays, giving the appearance of activation. To test this hypothesis, we serially diluted tartrate and added to FH or MDH assays without their normal substrate (fumarate or malate) in the reaction. We found that tartrate can drive both enzymes in the absence of their eponymous substrates with a similar reaction rate ( Fig 6D and 6E) . The Km value of tartrate was determined by MDH assay with Km = 1296 ± 33 µM ( Fig 6F) , much lower than malate, the normal substrate of MDH (Km = 225 ± 30 µM).
Discussion:
In our efforts to identify the small molecule probes for FH, we developed a quantitative highthroughput screening (qHTS) FH assay and screened a collection of small molecule libraries.
After several rounds of screening and counter screening, only one series of activators met all activity criteria in our study. Those compounds were not a substrate of FH, and they demonstrated direct binding to FH protein. This activator series enhanced the FH activity in the presence of its substrate. Our results suggest that these compounds are allosteric modulators of fumarate hydratase, however, further work is needed to optimize activity and confirm their mechanism of activation.
The series identified as FH activators is a group of phenyl-pyrrolo-pyrimidine-diones (Fig 2A and   Fig 3B) . The hit series consists of 12 active compounds and 9 inactive compounds. A structureactivity relationship (SAR) analysis with this limited set of compounds suggested that the nature of the substitution on the pyrrole nitrogen (R) was important for FH activation (Supplemental Table 1 ). Active compounds appeared to favor the attachment of a methylene unit to the pyrrole nitrogen followed by further substitution (see Figure 2A ). Attachment of additional substituents to this carbon, for example when R was branched such as a phenyl ring or a secondary or tertiary alkyl group, led to erosion in activity. Linear alkyl, phenethyl, and benzyl substituents on the pyrrole N were well tolerated. These data suggest that the pyrrole nitrogen might be important for the compound's interaction with the protein target and that an uncrowded environment around it might be essential for its binding to the target. With regard to the 5-phenyl ring the presence of a halide substitution (X = Cl or Br) appeared to be necessary for activity ( Supplemental Table 1) was used as a counter-assay to triage these false-positive compounds. However, the MDH counter-assay may triaged compounds that inhibit or activate both FH and MDH. As a common substrate for both FH and MDH, malate should be able to bind to the active sites of both enzymes, which suggests a structural similarity in active sites between two enzymes. The inhibitors which competitively bind to same active sites will be filtered out in MDH counter assay. As such, non-selective competitive inhibitors would be prone to exclusion by assay format. No inhibitors were identified in current study after screening a collection of 57,037 compounds. In a similar assay format, Kasbekar 12 also didn't identify any competitive inhibitors for tbFH after screening a collection of 479,984 compound. Instead, two inhibitors that bind to an allosteric regulatory site were found.
In summary, we developed a quantitative high-throughput screening (qHTS) FH assay and screened a collection of 57,037 small molecules. A series of phenyl-pyrrolo-pyrimidine-diones were identified as activators of human fumarate hydratase, which can serve as a starting point for further optimization and development as probes for the enzyme.
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